BridgeBio Pharma announced on Wednesday that its heart disease therapy acoramidis, marketed as Attruby in the U.S., demonstrated superior performance compared to Pfizer's competing drug tafamidis, sold under the brand name Vyndamax, in a real-world study.

The U.S. Food and Drug Administration approved Attruby in November 2024 for the treatment of transthyretin amyloid cardiomyopathy, a rare cardiac condition affecting an estimated 300,000 to 500,000 people worldwide. Pfizer has long held a dominant position in this therapeutic area with Vyndamax.

BridgeBio cited peer-reviewed data showing that acoramidis was associated with a 34% reduction in a composite measure of clinical deterioration events, a decline that was both statistically and clinically significant. This composite included factors such as intensification of diuretic therapy, which serves as an early indicator of worsening heart failure.

The findings, published in the medical journal Cardiology and Therapy, were based on U.S. Medicare claims data covering 170 patients who started acoramidis and 448 patients who initiated tafamidis between December 2024 and April 2025. Patient follow-up extended through July 2025, with an average observation period of approximately 4.6 months.

The company plans to present additional real-world data at a medical conference this autumn to further highlight the advantages of acoramidis over the competing therapy.